Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participant...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin J Am Soc Nephrol
Hlavní autoři: Bakris, George, Oshima, Megumi, Mahaffey, Kenneth W., Agarwal, Rajiv, Cannon, Christopher P., Capuano, George, Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Oh, Richard, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Jardine, Meg J., Perkovic, Vlado
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769025/
https://ncbi.nlm.nih.gov/pubmed/33214158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.10140620
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky